08:03 AM EDT, 10/09/2024 (MT Newswires) -- Viking Therapeutics ( VKTX ) shares were up more than 2% in premarket activity after saying it received positive data from a phase 1b clinical trial of VK021 for patients with X-linked adrenoleukodystrophy.

The company said the study showed VK0214, a novel small molecule agonist of the thyroid hormone receptor beta, to be "safe and well-tolerated" following daily dosing over a 28-day period. "Significant" reductions were also observed in plasma levels of very long-chain fatty acids and other lipids compared with a placebo, the company said.

Adrenoleukodystrophy is a genetic disease that affects nerve cells in the brain and can lead to a vegetative state or death.

Price: 68.02, Change: +1.34, Percent Change: +2.01